This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

-16.7%

Wachstumsrate der Gewinne

-2.4%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	-14.6%
Wachstumsrate der Einnahmen	24.4%
Eigenkapitalrendite	n/a
Netto-Marge	-391.9%
Letzte Ertragsaktualisierung	30 Jun 2022

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Epizyme Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

DB:EPE Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 22	53	-208	115	114
31 Mar 22	38	-236	125	123
31 Dec 21	37	-251	134	123
30 Sep 21	34	-267	137	165
30 Jun 21	33	-257	136	165
31 Mar 21	22	-251	133	102
31 Dec 20	16	-232	125	102
30 Sep 20	12	-222	114	0
30 Jun 20	14	-202	100	0
31 Mar 20	17	-192	83	0
31 Dec 19	24	-173	68	126
30 Sep 19	29	-140	57	0
30 Jun 19	23	-141	51	0
31 Mar 19	30	-122	47	0
31 Dec 18	22	-124	44	0
30 Sep 18	12	-137	40	0
30 Jun 18	12	-137	38	0
31 Mar 18	10	-136	38	0
31 Dec 17	10	-134	37	0
30 Sep 17	10	-133	36	0
30 Jun 17	17	-120	35	0
31 Mar 17	8	-120	31	0
31 Dec 16	8	-110	28	0
30 Sep 16	8	-97	27	0
30 Jun 16	2	-96	26	0
31 Mar 16	2	-94	25	0
31 Dec 15	3	-132	24	0
30 Sep 15	12	-125	23	0

Qualität der Erträge: EPE is currently unprofitable.

Wachsende Gewinnspanne: EPE is currently unprofitable.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: EPE is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.

Beschleunigtes Wachstum: Unable to compare EPE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: EPE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.1%).

Eigenkapitalrendite

Hohe Eigenkapitalrendite: EPE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

Epizyme Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.63 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.69 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.63 loss in 2Q 2021)

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.69 loss in 1Q 2021)

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought €424k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.50

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: €9.30

Independent Director recently bought €51k worth of stock

New 90-day low: €9.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Epizyme, Inc. Announces Executive Promotions

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: €10.00

First half earnings released

New 90-day low - €11.60

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren